Along with the rising heat, sales of oral electrolyte Electral have jumped over 26% year-on-year. Sales of the dehydration cure were the highest among the top 10 rankers, month-on-month, according to a Times of India report.
Based on market research from IQVIA, the report found that sales of Electral grew 28% month-on-month, selling Rs 72 crore in the domestic market.
Rising rales propelled the brand to fourth in the market in April, from 20th in March.
India’s pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter.
April saw the market bounce back with 9% growth year-on-year, on the back of gastroenterology medicines, Pan and Pan D, which increased sales by 19% and 17% respectively, liver therapies, Liv-52 by 17%, and Udiliv 28%.April saw anti-diabetic therapy Mixtard top the list with sales of Rs 75 crore, followed closely by respiratory medication Foracort (Rs 74 crore) and antidiabetic pill Glycomet-GP (Rs 73 crore)Acute therapy – mainly painkillers and anti-infectives – has shown a growth of 6%. As against this, chronic medication – prescribed for long-term ailments – has grown more than double at 13%. For past six months, chronic has outperformed acute therapy.
The jump in April sales saw Sun Pharma, Mankind, Intas and Torrent benefit, with Sun maintaining its position at the top of the market, holding on to its 8% market share.
April proved to be healthy for both MNCs and domestic companies, with both posting growth of 8% each. On a MAT (moving annual total) basis, the pharma retail market grew over 7% at Rs 2.2 lakh crore.
With inputs from TOI
